← Browse by Condition
Medical Condition

neuromyelitis optica spectrum disorder

Total Trials
3
Recruiting Now
3
Trial Phases
Various

ClinicalMetric tracks all active clinical trials for neuromyelitis optica spectrum disorder sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — neuromyelitis optica spectrum disorder Clinical Trials

How many clinical trials are currently recruiting for neuromyelitis optica spectrum disorder?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for neuromyelitis optica spectrum disorder, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for neuromyelitis optica spectrum disorder?
neuromyelitis optica spectrum disorder research spans multiple clinical trial phases. Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a neuromyelitis optica spectrum disorder clinical trial?
Eligibility criteria for neuromyelitis optica spectrum disorder trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
Tongji Hospital 1 trial
University of Bern 1 trial
Alexion Pharmaceuticals, Inc. 1 trial

Recruiting Clinical Trials

NCT06502015
Recruiting
Biomarkers in Autoimmune Disease of Nervous System
Enrollment
50,000 pts
Location
China
Sponsor
Tongji Hospital
View Trial →
NCT05017142
Recruiting
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
Enrollment
500 pts
Location
Switzerland
Sponsor
University of Bern
View Trial →
NCT05966467
Recruiting
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
Enrollment
122 pts
Location
United States, Argen...
Sponsor
Alexion Pharmaceuticals, Inc.
View Trial →

Related Conditions

multiple sclerosis (2) acute disseminated encephalomyelitis (2) autoimmune diseases of the nervous system (1) guillain barre syndrome (1) autoimmune encephalitis (1) stiff person syndrome (1) myasthenia gravis (1) chronic inflammatory demyelinating polyradiculoneuropathy (1) idiopathic inflammatory myopathies (1) autoimmune diseases (1) optic neuritis (1) transverse myelitis (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology